- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07850284
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
Copia de seguridad de contactos de estudio
- Nombre: Sarah Aug
- Número de teléfono: 507-538-1307
Ubicaciones de estudio
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic in Rochester
-
Contacto:
- Sarah Aug
- Número de teléfono: 507-538-1301
-
Investigador principal:
- Nadine Abdallah, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients age ≥ 18 years who have a diagnosis of MM and/or AL amyloidosis and are planned to start treatment at Mayo Clinic or another treatment facility
Descripción
Inclusion Criteria:
- Age >= 18 years
- Diagnosis of MM or AL based on IMWG diagnostic criteria
- Planned to start a new treatment within 14 days (+/-7 days)
- Able to provide written informed consent
Exclusion Criteria:
- Not able to give informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Observational
Patients are enrolled in the Quality of life text message system and receive SMS text messages and complete questionnaires daily for 3 months on study. |
Non-interventional study
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Engagement (Aim 1) - daily and weekly response rates
Periodo de tiempo: Up to 3 months
|
Engagement will be evaluated by daily and weekly response rates. A response rate of ≥60% to daily prompts (e.g., ≥4 days per week) will be considered acceptable engagement. |
Up to 3 months
|
|
Engagement (Aim 1) - uninterrupted participation
Periodo de tiempo: Up to 3 months
|
Engagement will be evaluated by the duration (number of days) of uninterrupted participation (e.g., consecutive response to daily prompts with missed days). |
Up to 3 months
|
|
Engagement (Aim 1) - complete symptom data
Periodo de tiempo: Up to 3 months
|
Engagement will be evaluated by the proportion of days with complete symptom data entered by participants. |
Up to 3 months
|
|
Acceptability (Aim 1) - CSQ-8
Periodo de tiempo: Up to 3 months
|
Acceptability will be measured using a post study survey: Client Satisfaction Questionnaire-8 (CSQ-8). The CSQ-8 is a self-report questionnaire used to measure general client satisfaction. It consists of 8 questions answered on a 4-point scale (e.g., quite dissatisfied, mildly dissatisfied, mostly satisfied, very satisfied). Total scores range from 8 to 32 with higher scores indicating higher satisfaction. |
Up to 3 months
|
|
System-generated alerts (Aim 2)
Periodo de tiempo: Up to 3 months
|
Will determine the proportion of alerts that prompt documented clinical actions (e.g., triage calls, provider outreach, medication adjustments, referrals, and/or unplanned visits). Alerts will be considered effective if ≥30% of alerts prompt clinical actions. |
Up to 3 months
|
|
Symptom and Quality of Life (QOL) trajectories (Aim 3) - PROMIS-29
Periodo de tiempo: Baseline to 3 months
|
Daily symptom and quality of life (QOL) trajectories will be modeled across treatment cycles. The Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) is used to assess patient-reported outcomes over the past 7 days across seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, social roles participation, and pain interference. Scores are scaled so that an average person would have a score of 50. Higher scores indicate more of the item being measured. Raw scores are converted to T-scores, with higher scores indicating better quality of life (QOL). Changes in PROMIS-29 scores will be evaluated using established minimal clinically important differences (MCIDs). Clinically meaningful deterioration will be defined as ≥ 2-point worsening in symptom severity, emergence of new severe symptoms, and deterioration in QOL scores in ≥20% of patients. |
Baseline to 3 months
|
|
Symptom and QOL trajectories (Aim 3) - SF-36
Periodo de tiempo: Baseline to 3 months
|
Daily symptom trajectories will be modeled across treatment cycles. The 36-Item Short Form Survey (SF-36) is used to measure patient health and disability. Participants rate items on a scale of 1 (all of the time) to 6 (none of the time) or 1 (not at all) to 5 (extremely) with higher scores indicating greater quality of life. Changes in SF-36 scores will be evaluated using established MCIDs. Clinically meaningful deterioration will be defined as ≥ 2-point worsening in symptom severity, emergence of new severe symptoms, and deterioration in QOL scores in ≥20% of patients. |
Baseline to 3 months
|
|
Change in Frailty status (Aim 4) - IMWG-FI
Periodo de tiempo: Baseline to 3 months
|
Frailty will be assessed using the International Myeloma Working Group-Frailty Index (IMWG-FI). The IMWG-FI will be analyzed as a continuous and categorical variable; patients will be classified into 3 categories (fit, intermediate fit, or frail). Total scores range from 0-5, with a score of 0 indicating fit, a score of 1 indicating intermediate fitness, and a score of ≥2 indicating frailty. |
Baseline to 3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nadine H. Abdallah, MD, Mayo Clinic in Rochester
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades metabólicas
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Deficiencias de proteostasis
- Amilosis
- Enfermedades Nutricionales y Metabólicas
- Enfermedades hemic y linfáticas
- Amiloidosis de cadena ligera de inmunoglobulina
- Mieloma múltiple
Otros números de identificación del estudio
- 26-002036
- NCI-2026-06651 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .